Day: April 30, 2025

2024 investments in seismic and other exploration work at Kruh Block set the stage for new drilling in the second half of 2025 JAKARTA, INDONESIA AND DANVILLE, CA, April 30, 2025 (GLOBE NEWSWIRE) — Indonesia Energy Corporation (NYSE American: INDO) (“IEC”), an oil and gas exploration and production company focused on Indonesia, today announced that it has filed today its annual report on Form 20-F which contains its financial and operating results for the year ended December 31, 2024. Also provided in that report is an update on IEC’s planned drilling activity for the second half of 2025. During 2024, IEC curtailed drilling activity at its Kruh Block asset in lieu of investing in seismic and other exploration work intended to maximum the return on new drilling. That drilling is expected to commence in the second half...

Hamilton, Bermuda, April 30, 2025 (GLOBE NEWSWIRE) —Management to host conference call today, April 30, at 8:00 a.m. EDT RNA delivery business progressing with platform development, new applications and collaborations Plans to partially spin off RNA delivery business Cash used in operations more than halved in 2024 – finished year with shareholders’ equity of $6.6 million  Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update and reported its full year 2024 financial results. “Altamira made great progress in its core business of RNA delivery in 2024,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman, and CEO. “The successful...

Strong quarterly results driven by enhanced portfolio diversification EDMONTON, Alberta, April 30, 2025 (GLOBE NEWSWIRE) — Capital Power Corporation (TSX: CPX) today released financial results for the quarter ended March 31, 2025. HighlightsEntered into a definitive agreement to acquire two natural gas-fired power generation facilities located in the PJM1 market for ~$3.0 billion (US $2.2 billion), adding ~2.2 GW of capacity to our U.S. flexible generation2 portfolio Continued progressing five Ontario growth projects to add ~350 MW of long-term contracted capacity Commenced construction of the Hornet Solar project in North Carolina Generated adjusted funds from operations (AFFO) of $218 million and net cash flows from operating activities of $210 million Generated adjusted EBITDA of $367 million and a net income of $150 million“By...

DANBURY, Conn., April 30, 2025 (GLOBE NEWSWIRE) — FuelCell Energy (NASDAQ:FCEL) today announced a key commercial leadership transition. Industry veteran Mike Hill was appointed as the company’s new Chief Commercial Officer, replacing Mark Feasel. Hill brings extensive commercial experience in power generation, water, and hydraulics from his career with globally recognized companies, including General Electric, ABB, and, most recently, Danfoss Power Systems. FuelCell Energy President and CEO Jason Few said, “We are pleased to welcome Mike to FuelCell Energy and look forward to working with him to capitalize on the growing resurgence in electricity demand that will be met with distributed power platforms. He has built a reputation as a transformational growth sales leader, and we are excited to support his agenda to drive top-line...

DENVER, April 30, 2025 (GLOBE NEWSWIRE) — authID® (Nasdaq: AUID) (“authID”), a leading provider of biometric identity verification and authentication solutions, today announced the Company will report financial results for the first quarter ended March 31, 2025 on Thursday, May 13, 2025, after the market close. Following issuance of the earnings release, authID Chief Executive Officer Rhon Daguro and Chief Financial Officer Ed Sellitto will host a webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update. To participate on the live conference call, please access this registration link and you will be provided with dial-in details. To avoid delays, participants are encouraged to dial into the conference call 15 minutes ahead of the scheduled start time. A live webcast of the call will also be available...

Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits Positive delayed-type hypersensitivity (DTH) (p = 0.001) and a favorable Neutrophil-to-Lymphocyte Ratio (NLR) (p = 0.02) linked to longer progression-free survival (PFS) in Phase 3 patients Presence of Circulating Tumor Cells (CTC) after patients’ initial Phase 3 treatment supports role as negative prognostic marker (p = 0.04) Bria-IMT Phase 3 regimen was well-tolerated with a preferred tolerability profilePHILADELPHIA and VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin  Data supports ongoing Phase 1 clinical trial for CT-95   PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced preclinical and translational data regarding the Company’s clinical asset, CT-95, a mesothelin x CD3 TCE was presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025 in Chicago, IL.  “There is a high unmet need for effective treatments in mesothelin expressing cancers. CT-95 is affinity tuned and avidity enhanced to concentrate drug activity within the...

ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The notification from Nasdaq confirms that for the last 13 consecutive business days, the closing bid price of the Company’s ordinary shares was at or above $1.00 per share. Accordingly, Nasdaq considers the matter closed. About Quoin Pharmaceuticals Ltd.Quoin Pharmaceuticals Ltd. is a late...

MONTREAL, April 30, 2025 (GLOBE NEWSWIRE) — NanoXplore Inc. (“NanoXplore”) (TSX: GRA and OTCQX: NNXPF) is pleased to hold a webcast to discuss the results of its third quarter ended March 31st, 2025, on Wednesday, May 14, 2025, at 10:00 a.m. Eastern Time. The financial results will be released on Tuesday, May 13, 2025, after the market close.  Details of the Q3 Webcast When: May 14, 2025, at 10:00 a.m. Eastern Time Webcast: To listen to the live webcast, please join and register at: https://edge.media-server.com/mmc/p/ngnxomuc or via our website under Events and Presentations in our Investors section at www.nanoxplore.ca A replay of the event will be available at the above webcast link or in the Investors section under Events and Presentations of the Company’s website at www.nanoxplore.ca. About NanoXplore Inc. NanoXplore is a...